Homocyst(e)ine and coronary artery disease: Clinical evidence and genetic and metabolic background

Archives of Internal Medicine

Volumn 157, Issue 20, 1997, Pages 2299-2308

  Moghadasian, Mohammed H ^a   McManus, Bruce M ^b   Frohlich, Jiri J ^a,b  

^a Healthy Heart Program   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE; VITAMIN B GROUP;

AGE; AMINO ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIET SUPPLEMENTATION; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING;

EID: 0030709337     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.20.2299     Document Type: Article

References (153)

1. Loehrer FMT, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood Sadenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol. 1996;16:727-733.
2. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
3. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
4. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: the Atherosclerosis Risk in Communities study. Circulation. 1993;87:1107-1113.
5. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase:an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991;48:536-545.
6. 6, pyridoxal phosphate and folate. Can J Cardiol. 1993;9:81E. Abstract.
7. Genest J Jr,McNamara JR, Upson B, et al. Prevalence of familial hypernomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb. 1991;11:1129-1136.
8. Robinson K, Mayer EL, Miller DP, et al. Hyper-homocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 1995;92:2825-2830.
9. Genest JJ Jr, McNamara JR, Salem DN, et al. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
10. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
11. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis. 1994;106:9-19.
12. Kang SS, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest 1986;77:1482-1486.
13. Israelsson B, Brattström LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis. 1988;71:227-233.
14. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis. 1989;79:139-146.
15. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B. Hyperhomocysteinemia in stroke: prevalence, cause and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
16. Mölgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med. 1992;231:273-279.
17. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke. 1990;21:572-576.
18. Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
19. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattström L. Plasma homocysteine in acute myocardial infarction: homo-cysteine-lowering effect of folic acid. J Intern Med. 1995;237:381-388.
20. Hopkins PN, Wu LL, Wu J, et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1995;15:1314-1320.
21. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron Artery Dis. 1990;1:215-220.
22. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994;59:940-948.
23. Arnesen E, Resfum H, Bonaa KH, et al. Serum total homocysteine and coronary heart disease, int J Epidemiol. 1995;24:704-709.
24. Van den Berg M, Stehouwer DA, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol. 1996;16:165-171.
25. Selhub J, Jacques F, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
26. Amundsen T, Ueland PM, Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arferioscler thromb Vasc Biol. 1995;15:1321-1323.
27. Den Heijer M, Koster T, Blom HU, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
28. Den Heijer M, Blom HU, Gerrits WB, et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet. 1995;345:882-885.
29. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocys-t(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb. 1994;14:1080-1083.
30. Fermo I, Vigano-D'Angelo S, Paroni R, et al. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 1995;123:747-753.
31. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res. 1991;51:828-835.
32. Wu JT, Wu L, Wilson W. Increased levels of plasma homocysteine in patients with various carcinomas. Ir J Med Sci. 1995;164:29A, Abstract.
33. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327:1832-1835.
34. MRC Vitamin Study Research Group. Prevention of neural-tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131-137.
35. Gerritsen T, Vaughn JG, Waisman HA. The identification of homocysteine in the urine. Biochem Biophys Res Commun. 1962;9:493-496.
36. Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child. 1962;37:505-513.
37. Mudd SH, Finkelstein JD, Irreverre F, Laster L. Homocystinuria: an enzymatic defect. Science. 1964;143:1443-1445.
38. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a com mon mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
39. Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995;346:1070-1071.
40. Engbersen AMT, Franken DG, Bores GHJ, et al. Thermolabile 5, 10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinaemia. Am J Hum Genet. 1995;56:142-150.
41. Beckman DR, Hoganson G, Berlow S, Gilbert EF. Pathological findings in 5, 10-methylenetetrahydrofolate reductase deficiency. Birth Defects. 1987;23:47-64.
42. Kang S, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993;88:1463-1469.
43. De Franchis R, Mancini FP, D'Angelo A, et al. Elevated total plasma homocysteine and 677C→T mutation of 5, 10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet. 1996;59:262-264.
44. Malinow MR. Hyperhomocyst(e)inemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation. 1990;81:2004-2006.
45. Mudd SH. Homocystinuria and homocysteine metabolism: selected aspects. In: Nyhan WL, ed. Heritable Disorders of Amino Acid Metabolism. New York, NY: John Wiley & Sons Inc; 1974:429-451.
46. Brenton DP, Cusworth DC. The response of patients with cystathionine synthase deficiency to pyridoxine. In: Carson NAJ, Raine DN, eds. Inherited Disorders of Sulphur Metabolism. London, England: Churchill Livingstone; 1971:264-274.
47. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 1985;37:1-31.
48. Jacob RA, Wu M, Henning SM, Swendseid ME. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr. 1994;124:1072-1080.
49. Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr. 1994;124:1927-1933.
50. Alien RH, Stabler SP, Savage DG, Lindenbaum J. Diagnosis of cobalamin deficiency, I: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol. 1990;34:90-98.
51. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulindependent diabetes mellitus: effects of parenteral methylcobalamin treatment. Atherosclerosis. 1993;103:149-157.
52. Refsum H, Heiland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem. 1985;31:624-628.
53. Stabler SP, Marcell PD, Podell ER, Allen RH. Quantification of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem. 1987;162:185-196.
54. Evrovski J, Callaghan M, Cole DEC, et al. Determination of homocysteine by HPLC with pulsed integrated amperometry. Clin Chem. 1995;41:757-758.
55. Fortin L, Genest J. Measurement of homocyst(e)ine in the prediction of atherosclerosis. Clin Biochem. 1995;28:155-162.
56. Jacobsen DW, Gatautis VJ, Green R. Determination of plasma homocysteine by high performance liquid chromatography with fluorescence detection. Anal Biochem. 1989;178:208-214.
57. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by highperformance liquid chromatography with fluorescence detection. J Chromatogr. 1991;565:441-446.
58. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMX analyzer. Clin Chem. 1995;41:991-994.
59. Chu RC, Hall CA. The total serum homocysteine as an indicator of vitamin 612 and folate status. Am J Clin Palhol. 1988;90:446-449.
60. Chadefaux B, Coude M, Hamet M, Aupetit J, Kamoun P. Rapid determination of total homocysteine in plasma. Clin Chem. 1989;35:2002.
61. Stabler SP, Lindenbaum J, Savage DG, Allen RH. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood. 1993;81:3403-3413.
62. Andersson A, Brattstrom L, Isaksson A, Israelsson B, Hultberg B. Determination of homocysteine in plasma by ion-exchange chromatography. Scand J Clin Lab Invest. 1989;49:445-450.
63. Hultberg B, Andersson A, Arnadottir M. Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron. 1995;70:62-67.
64. Berg K, Malinow MR, Kierulf P, Upson B. Population variation and genetics of plasma homocyst(e)ine level. Clin Genet 1992;41:315-321.
65. Strydom AJC, Vorster HH, Kahlberg NE, Sullivan C, Barnard HC. A comparative study in humans of their plasma homocysteine and cholesterol levels in relation to diet. Clin Chem. 1990;36:954.
66. Bostom AG, Shemin D, Lapane L, et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis. 1995;114:93-103.
67. Malinow MR, Levenson J, Giral P, et al. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis. 1995;114:175-183.
68. Jacobsen DW, Gatautis V, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994;40:873-881.
69. Ubbink JB, Becker PJ, Vermaak WJH, Delport R. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem. 1995;41:1033-1037.
70. Rasmussen K, Møller J, Lyngbak M, Pedersen AMH, Dybkjaer L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem. 1996;42:630-636.
71. Nygård O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995;274:1526-1533.
72. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol. 1993;40:230-234.
73. Ubbink JB, Vermaak WJH, Delport R, et al. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr. 1995;62:802-808.
74. Genest JJ Jr, Malinow MR. Homocyst(e)ineand coronary artery disease. Curr Opin Lipidol. 1992;3:295-299.
75. Taylor LM Jr, DeFrang RD, Harris EJ, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991 ;13:128-136.
76. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest. 1976;57:1079-1082.
77. Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulation. 1996;94:2154-2158.
78. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 ;324:1149-1155.
79. Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24-29.
80. Fau D, Peret J, Hadjiisky P. Effects of ingestion of high protein or excess methionine diets by rats for two years. J Nutr. 1988;118:128-133.
81. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1975;22:215-227.
82. Boushey CJ, Beresford AA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA. 1995;274:1049-1057.
83. Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
84. Nordström M, Kjellström T. Age dependency of cystathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis. 1992;94:213-221.
85. Wilcken DEL, Gupta VJ. Sulfur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulfide. Eur J Clin Invest. 1979;9:301-307.
86. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
87. Wouters MG, Moorrees MT, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest. 1995;25:801-805.
88. Anker G, Lonning PE, Ueland PM, et al. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. int J Cancer. 1995;60:365-368.
89. Andersson A, Hultberg B, Brattstrom L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem. 1992;30:377-379.
90. Van der Mooren MJ, Wouters MGAJ, Blom HJ, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest. 1994;24:733-736.
91. Thomson SB, Tucker DJ, Briggs MH. Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats. Steroids. 1984;44:531-538.
92. Bergmark C, Mansoor MA, Swedenborg J, et al. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50: effects of smoking and extent of disease. Eur J Vasc Surg. 1993;7:391-396.
93. Williams RR, Malinow MR, Hunt SC, et al. Hyperhomocyst(e)inemia in Utah siblings with early coronary disease. Coron Artery Dis. 1991;1:681-685.
94. Pryor WA, Stone K. Oxidants in cigarette smoke: radical, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci. 1993;686:12-28.
95. Mansoor MA, Bergmark C, Svardal AM, et al. Redox status and protein binding of plasma homocysteine and other aminthiols in patients with early-onset peripheral vascular disease. Arterioscler Thromb Vasc Biol. 1995;15:232-240.
96. Piyathilake CJ, Macalous M, Mine RJ, et al. Local and systemic effects of cigarette smoking on folate and vitamin B-12. Am J Clin Nutr. 1994;60:559-566.
97. Dastur DK, Quadros EV, Wadia NH, et al. Effect of vegetarism and smoking on vitamin B12, thiocyanate, and folate levels in the blood of normal subjects. BMJ. 1972;3:260-263.
98. Vermaak WJH, Ubbink JB, Barnard HC, et al. Vitamin B-6 nutrition status and cigarette smoking. Am J Clin Nutr. 1990;51:1058-1061.
99. Skovby F, Krassikoff N, Francke U. Assignment of the gene for cystathionine β-synthase to human chromosome 21 in somatic cell hybrids. Hum Genet. 1984;65:291-294.
100. Munke M, Kraus JP, Ohura T, Francke U. The gene for cystathionine β-synthase (CBS) maps to the subtelomeric region on human chromosome 21q and to proximal mouse chromosome 17. Am J Hum Genet. 1988;42:550-559.
101. Kraus JP. Molecular basis of phenotype expression in homocystinuria. J Inherit Metab Dis. 1994;17:383-390.
102. Kozich V, Kraus E, de Franchis R, et al. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine β-synthase alleles at the molecular level. Hum Mol Genet. 1995;4:623-629.
103. Kluijtmans LAJ, Blom HJ, Bores GHJ, et al. Two novel missense mutations in the cystathionine β-synthase gene in homocystinuric patients. Hum Genet. 1995;96:249-250.
104. Bores GHJ, Fowler B, Smals GH, et al. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet 1985;69:164-169.
105. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In:Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York, NY: Marcel Dekker Inc; 1992:183-236.
106. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGrawHill Book Co; 1995:3111-3128.
107. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/ phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet. 1995;56:1052-1059.
108. Goyette P, Summer JS, Milos R, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994;7:195-200.
109. Kang SS, Zhou J, Wong PWK, et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988;43:414-421.
110. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet. 1996;58:17-20.
111. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
112. Higginbottom MC, Sweetman L, Nyhan WL. A syndrome of methylmalonic aciduria, homocystinuria, megaloblastic anemia and neurological abnormalities in a vitamin B12-deficient breastfed infant of a strict vegetarian. N Engl J Med. 1978;299:317-323.
113. Stabler SP, Marcel PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by gas chromatography-mass spectrophotometry. J Clin Invest. 1988;81:466-474.
114. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med. 1994;96:239-246.
115. Olszewski AJ, Szostak WB, Bialkowska M, Rudnicki S, McCully KS. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Atherosclerosis. 1989;88:143-151.
116. UbbinkJB. Vitamin nutrition status and homocysteine: an atherogenic risk factor. Nutr Rev. 1994;52:383-387.
117. Refsum H, Ueland PM. Clinical significance of pharmacological modulation of homocysteine metabolism. Trends Pharmacol Sci. 1990;11:411-416.
118. Arnadottir M, Brattstrom L, Simonsen O, et al. The effect of high dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol. 1993;40:236-240.
119. Zimmermann MB, Shane B. Supplemental folic acid. Am J Clin Nutr. 1993;58:127-128.
120. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGrawHill Book Co; 1995:1279-1327.
121. Blankenhorn DH, Malinow MR, Mack WJ. Cholestipol plus niacin therapy elevates plasma homocyst(e)ine levels. Coron Artery Dis. 1991;2:357-360.
122. Starkebaum G, Harlan LA. Endothelial cell injury due to copper-catalyzed hydrogen perox ide generation from homocysteine. J Clin Invest 1986;77:1370-1376.
123. Dudman NPB, Hicks C, Lynch JF, Wilcken DEL, Wang J. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arierioscler Thromb. 1991;11:663-670.
124. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-inuced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res. 1980;18:113-121.
125. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med. 1974;291:537-543.
126. Clarke R, Naughten E, Cahalane S, et al. The role of free radicals as mediators of endothelial cell injury in hyperhomocysteinemia. Ir J Med Sci. 1992;161:561-564.
127. Panganamala RV, Karpen CW, Merola AJ. Peroxide-mediated effects of homocysteine on arterial prostacyclin synthesis. Prostaglandins Leukot Med. 1986;22:349-356.
128. Stamler JS, Osborne JA, Jaraki O, Rabbani LE. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308-318.
129. Fryer RH, Wilson BD, Gubler DB, et al. Homocysteine. a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993;13:1327-1333.
130. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr. 1996;126:1285S-1289S.
131. Van der Berg M, Bores GH, Franken DG, et al. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995;25:176-181.
132. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis. 1992;94:89-91.
133. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine endothelial cells. J Clin Invest. 1993;92:1381-1386.
134. Harker LA, Ross R. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-741.
135. McCully KS, Carvalho AC. Homocysteine thiolactone, N-homocysteine thiolactonyl retinamide, and platelet aggregation. Res Commun Chem Pathol Pharmacol. 1987;56:349-360.
136. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart M. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res. 1982;16:490-493.
137. Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria: evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993;92:1400-1406.
138. Giannini MJ, Coleman M, Innerfield I. Antithrom bin activity in homocystinuria. Lancet 1975;1:1094.
139. Palareti G, Coccheri S. Lowered antithrombin III activity and other clotting changes in homocystinuria: effects of pyridoxine-folate regimen. Haemostasis. 1989;19:24-28.
140. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909-1916.
141. Von Eckardstein A, Malinow MR, Upson B. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb. 1994;14:960-964.
142. McCully KS. Chemical pathology of homocysteine, I: atherogenesis. Ann Clin Lab Sci. 1993;23:477-493.
143. 2C leukemic lymphocytes, Biochimie. 1986;68:723-730.
144. Naruszewicz M, Mirkiewicz E, Olszewski AJ, McCully KS. Thiolation of low density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovasc Dis. 1994;4:70-77.
145. Harker LA, Harlen JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and atherosclerosis in baboons. Circ Res. 1983;53:731-739.
146. Tsai J-C, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 1994;91:6369-6373.
147. Van Aken BE, Jansen J, Reitsma PH, et al. Homocysteine increased IL-6 production by the human monocytic cell line monomac-6. J Vasc Res. 1996;33:103.
148. Olszewski AJ, McCully KS. Homocysteine metabolism and oxidative modification of proteins and lipids. Free Radie Biol Med. 1993;14:683-693.
149. Schlüssel E, Preibisch G, Pütter S, Elstner EF. Homocysteine-induced oxidative damage: mechanisms and possible roles in neurodegenerative and atherogenic processes. Z Naturforsch. 1995;50C:699-707.
150. Toborek M, Kopieczna-Grzebieniak E, Drózdz M, Wieczorek M. Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis. 1995;115:217-224.
151. Frohlich JJ. Lipoproteins and homocyst(e)ine as risk factors for atherosclerosis: assessment and treatment. Can J Cardiol. 1995;11:18C-23C.
152. Munshi MM, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism. 1996;45:133-135.
153. Nygård O, Nordrehauge JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.